A coumermycin/novobiocin-regulated gene expression system
CA 2523879 C · Owner: National Research Council Of Canada · Inventors: Zhao, Hui-Fen; Shen, Shi-Hsiang
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A chimeric transactivator comprises a transcription activation domain a , repressor protein DNA binding domain and the bacterial DNA gyrase B subunit. A target gene is operatively linked to operator DNA sequences recognized by the repressor binding domain. The addition of the antibiotic coumermycin results in a coumermycin-switched dimerization of the transactivator which then binds , to operator DNA sequences and activates transcription of the target gene. The addition of novobiocin switches off expression of the target gene by abolishing coumermycin-induced dimerization of the transactivator.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 9, 2004 and granted March 19, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 9, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 9, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.